The Comprehensive Guide to Octreotide 30mg Injection (Long-Acting Depot) In the management of neuroendocrine tumors and severe endocrine disorders, Octreotide 30mg Injection is a critical, long-acting therapeutic agent. As a premier pharmaceutical exporter from India, Ernest Oncology (a group of Ernest Pharmaceutical Pvt. Ltd.) ensures that this life-improving medication is available to healthcare systems in London, New York, Sydney, Johannesburg, and beyond. Product SpecificationsFeatureDetailsBrand NameErnest-Oncology (Octreotide Acetate)Strength30 mgDosage FormExtended-release suspension for intramuscular injectionPrimary IndicationAcromegaly, Carcinoid Syndrome, VIP-secreting tumorsStorageStore at 2°C to 8°C (36°F to 46°F). Protect from light. Mechanism of Action: How It Works Hormone Suppression: It is a more potent inhibitor of growth hormone, glucagon, and insulin than natural somatostatin. Reduction of Secretion: It acts on the digestive organs to decrease blood flow and inhibits the release of various gastrointestinal hormones such as serotonin, gastrin, and vasoactive intestinal peptide (VIP). Symptom Management: By suppressing these chemicals, it controls severe diarrhea and flushing caused by neuroendocrine tumors. Therapeutic Indications & Administration Acromegaly: For the long-term maintenance treatment of acromegaly in patients who respond to short-acting octreotide. Carcinoid Tumors: Symptomatic management of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors. VIPomas: Control of profuse watery diarrhea linked to vasoactive intestinal peptide-secreting tumors. Formulation Type: Extended-release (depot) injection. Administration Route: Administered as a deep intramuscular injection, typically in the gluteal muscle (buttocks) once every 4 weeks. Preparation: It must be brought to room temperature prior to reconstitution and injection. Clinical Side Effects & Safety Gallbladder Issues: Long-term use increases the risk of gallstones and related complications such as cholecystitis or pancreatitis. Monitor via ultrasound. Blood Sugar Imbalances: It may alter blood sugar regulation. Patients with diabetes may require adjustments to their insulin or oral hypoglycemic doses. Cardiovascular Effects: Bradycardia (slow heart rate) and conduction abnormalities have been reported. Common Side Effects: Injection site pain, nausea, diarrhea, abdominal discomfort, and gas. Contraindications: Hypersensitivity to octreotide or any of the components. Use with caution during pregnancy or breastfeeding. Why Source from Ernest Oncology? United Kingdom (London): Supplying cost-effective healthcare solutions for specialized clinics and NHS-affiliated trusts. USA: Delivering bulk quantities that comply with FDA and international safety benchmarks. Australia: Ensuring access to specialized supply chains (such as the Special Access Scheme). South Africa: Bridging critical therapeutic gaps by providing high-tier pharmaceutical exports from India. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 📦 Business Type: Exporter | Bulk Supplier | Distributor 🌐 Websites: www.oncologymedicinesupplier.com www.ernestpharmaceuticals.com www.ernestvision.com www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383
Washington, USA
08048034998
+919405476170
Chat with us
Chat with us